Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

BLACKPINK’s Impact: YG Entertainment’s Earnings Forecast Dips, Target Price Lowered

Daniel Kim Views  

The fourth quarter performance of YG Entertainment (122870) has fallen short of market expectations, and future performance is expected to fluctuate depending on the activities of BLACKPINK.

Hana Securities revised its operating profit outlook for YG Entertainment, assuming changes in BLACKPINK’s activities, on the 4th to about $37 million in 2024 and about $67 million in 2025. As a result, the target stock price was lowered by 18% to about $48 as of 2025.

YG Entertainment’s fourth-quarter sales were about $82 million, a 12% decrease from the previous year, and operating profit fell 98% to about $300,500, significantly missing the consensus. It is estimated that the subsidiary YG PLUS performed worse than expected. Although BABYMONSTER debuted, there were no album comebacks, and the assessment is that MD sales were decent, reflecting TREASURE’s Korea and Japan tours.

“In the first quarter, artist comeback activities will be limited due to BABYMONSTER’s single comeback, but in the second quarter, the comeback of TREASURE and BABYMONSTER’s albums and 22 Asian tours including TREASURE’s first half of Japan’s arena and dome will be reflected,” predicted Lee Ki Hoon, a researcher at Hana Securities.

Recently, the largest shareholder purchased about 462,000 shares (about $15 million) at about $31.5~$33, which is judged to infer high confidence in BABYMONSTER, not only because the stock price has fallen significantly.

“If such expectations are realized where the performance and stock price dependence on a single IP has increased, both performance and valuation can be significantly normalized,” said Researcher Lee Ki Hoon. “There are also plans for a regular album in the fall, so a fast comeback in the early debut will continue.”

However, high volatility is expected depending on the presence or absence of BLACKPINK’s activities.

BLACKPINK is expected to repeat large-scale tours and long hiatuses. The original 2024 performance forecast assumed a comeback before the Olympics. Still, suppose it is believed that a comeback in the fourth quarter will be followed by a world tour in 2025 and a comeback in 2026. In that case, the annual performance volatility is expected to increase depending on the presence or absence of BLACKPINK’s activities.

“As BLACKPINK’s performance dependence is high, the stock price is also likely to repeat similar fluctuations,” said Researcher Lee Ki Hoon. “To solve this, BABYMONSTER that A Hyeon joined needs to be strong enough to break the strong competition structure of female idols.”

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LATEST] Latest Stories

  • BMW's Next-Gen EV: The Bold New i3 Touring Concept Revealed
  • LEGO Technic Ferrari SF-24 F1 Car: A 1,361-Piece Tribute to Ferrari’s 2024 F1 Season
  • Hyundai’s Ioniq 6 Just Took the Top Spot in J.D. Power’s EV Ownership Study
  • Jeep’s Recon: The Next-Gen 600HP Electric SUV Ready to Tackle the Market
  • Tesla Issues Recall for 376,000 Vehicles Due to Steering Assist Malfunction
  • Ferrari Reveals 499P Livery and Driver Lineup for 2025 World Endurance Championship

You May Also Like

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE 

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE 

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE 

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE 

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE 

Must-Reads

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE 

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE 

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE 

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE 

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE 

Share it on...